Back to Search
Start Over
Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs
- Source :
- European Respiratory Journal, European Respiratory Journal, European Respiratory Society, In press, ⟨10.1183/13993003.02338-2020⟩, The European Respiratory Journal, article-version (VoR) Version of Record, The European respiratory journal, European Respiratory Journal, European Respiratory Society, 2021, 57, pp.2002338. ⟨10.1183/13993003.02338-2020⟩, European Respiratory Journal, 2021, 57, pp.2002338. ⟨10.1183/13993003.02338-2020⟩
- Publication Year :
- 2020
-
Abstract
- Conventional molecular tests for detecting Mycobacterium tuberculosis complex (MTBC) drug resistance on clinical samples cover a limited set of mutations. Whole-genome sequencing (WGS) typically requires culture. Here, we evaluated the Deeplex Myc-TB targeted deep-sequencing assay for prediction of resistance to 13 anti-tuberculous drugs/drug classes, directly applicable on sputum. With MTBC DNA tests, the limit of detection was 100–1000 genome copies for fixed resistance mutations. Deeplex Myc-TB captured in silico 97.1–99.3% of resistance phenotypes correctly predicted by WGS from 3651 MTBC genomes. On 429 isolates, the assay predicted 92.2% of 2369 first- and second-line phenotypes, with a sensitivity of 95.3% and a specificity of 97.4%. 56 out of 69 (81.2%) residual discrepancies with phenotypic results involved pyrazinamide, ethambutol and ethionamide, and low-level rifampicin or isoniazid resistance mutations, all notoriously prone to phenotypic testing variability. Only two out of 91 (2.2%) resistance phenotypes undetected by Deeplex Myc-TB had known resistance-associated mutations by WGS analysis outside Deeplex Myc-TB targets. Phenotype predictions from Deeplex Myc-TB analysis directly on 109 sputa from a Djibouti survey matched those of MTBSeq/PhyResSE/Mykrobe, fed with WGS data from subsequent cultures, with a sensitivity of 93.5/98.5/93.1% and a specificity of 98.5/97.2/95.3%, respectively. Most residual discordances involved gene deletions/indels and 3–12% heteroresistant calls undetected by WGS analysis or natural pyrazinamide resistance of globally rare “Mycobacterium canettii” strains then unreported by Deeplex Myc-TB. On 1494 arduous sputa from a Democratic Republic of the Congo survey, 14 902 out of 19 422 (76.7%) possible susceptible or resistance phenotypes could be predicted culture-free. Deeplex Myc-TB may enable fast, tailored tuberculosis treatment.<br />The novel Deeplex Myc-TB molecular assay shows a high degree of accuracy for extensive prediction of susceptibility and resistance to 13 anti-tuberculous drugs, directly achievable without culture, which may enable fast, tailored tuberculosis treatment https://bit.ly/3bAvcAt
- Subjects :
- 0301 basic medicine
Pulmonary and Respiratory Medicine
030106 microbiology
Respiratory System
Antitubercular Agents
Drug resistance
Microbial Sensitivity Tests
[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Deep sequencing
Mycobacterium
03 medical and health sciences
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Tuberculosis, Multidrug-Resistant
medicine
Humans
Tuberculosis
Deeplex Myc-TB may enable fast
Ethambutol
Genetics
Whole genome sequencing
Science & Technology
biology
business.industry
High-Throughput Nucleotide Sequencing
Original Articles
Mycobacterium tuberculosis
Pyrazinamide
biology.organism_classification
[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology
3. Good health
030104 developmental biology
Mycobacterium tuberculosis complex
Pharmaceutical Preparations
Pulmonary Infections and Tuberculosis
Mutation
[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Ethionamide
tailored tuberculosis treatment
Human medicine
[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology
business
Life Sciences & Biomedicine
Rifampicin
medicine.drug
Subjects
Details
- ISSN :
- 13993003 and 09031936
- Volume :
- 57
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- The European respiratory journal
- Accession number :
- edsair.doi.dedup.....0b7809621102ce6836ad5b0de59e323c
- Full Text :
- https://doi.org/10.1183/13993003.02338-2020⟩